Scarica l'app Stockscreener
14.17
1.43%
0.20
Dopo l'orario di chiusura:
14.25
0.08
+0.56%
Precedente Chiudi:
$13.97
Aprire:
$14.495
Volume 24 ore:
5.56M
Relative Volume:
2.76
Capitalizzazione di mercato:
$1.44B
Reddito:
$45.97M
Utile/perdita netta:
$-508.80M
Rapporto P/E:
-2.5952
EPS:
-5.46
Flusso di cassa netto:
$-382.65M
1 W Prestazione:
-19.03%
1M Prestazione:
-32.78%
6M Prestazione:
-45.96%
1 anno Prestazione:
-49.61%
Intervallo 1D:
$13.54
$15.20
Intervallo di 1 settimana:
$13.54
$17.30
Portata 52W:
$13.54
$34.87
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Confronta NTLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| NTLA | 14.17 | 1.44B | 45.97M | -508.80M | -382.65M | -5.46 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Wells Fargo & Company Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat
CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest - BioPharma Dive
Intellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at Wedbush - MarketBeat
Chardan Capital Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $91.00 - MarketBeat
Intellia’s gene editing therapy shows early potential in rare heart condition - Clinical Trials Arena
CF Foundation Invests Up to $15 million in ReCode Therapeutics to Develop a Gene Editing Therapy - Yahoo Finance
Intellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year LowHere's Why - MarketBeat
Intellia Announces First Clinical Evidence from Ongoing - GlobeNewswire
Intellia's CRISPR Therapy Shows 90%+ Disease Protein Reduction in Key Clinical Trial | NTLA Stock News - StockTitan
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Gene Editing Tools Market Size, Growth Opportunities, - openPR
Sumitomo Mitsui Trust Group Inc. Has $64.72 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (FRA:38I) Operating Income : €-492.77 Mil (TTM As of Sep. 2024) - GuruFocus.com
When (NTLA) Moves Investors should Listen - Stock Traders Daily
Intellia Therapeutics' SWOT analysis: gene editing stock's progress and potential - Investing.com India
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace
3 Fast-Growing Stocks Analysts See Doubling in Price - sharewise
Oppenheimer Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00 - MarketBeat
Intellia Therapeutics price target lowered to $60 from $70 at Oppenheimer - TipRanks
Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus (NASDAQ:NTLA) - Seeking Alpha
Brookline Capital Management Forecasts NTLA FY2027 Earnings - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Call Transcript - MSN
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at StockNews.com - MarketBeat
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus - MSN
Intellia Therapeutics (NASDAQ:NTLA) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? - MSN
Intellia Earnings: Early-Stage Pipeline Makes Progress; Shares Attractive for Long-Term Investors - Morningstar
Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $55.00 by Analysts at Barclays - MarketBeat
Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlight - GuruFocus.com
Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... - Yahoo Finance Australia
ARK Investment Management LLC Buys 659,651 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics price target lowered to $55 from $76 at Barclays - TipRanks
Intellia Therapeutics Reports Q3 2024 Financial Progress - TipRanks
Intellia Therapeutics price target lowered to $40 from $41 at JonesResearch - TipRanks
Intellia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Intellia Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com
Intellia Therapeutics reports Q3 EPS ($1.34), consensus ($1.39) - TipRanks
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - The Manila Times
Intellia (NTLA) Advances Phase 3 Trials Despite $135.7M Loss; $944.7M Cash Runway to 2026 | NTLA Stock News - StockTitan
Harbor Capital Advisors Inc. Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Data UnderwhelmsIntellia's Cash, Data And Competition Are A Challenging Story - Seeking Alpha
This Beaten-Down Stock Could Soar by 354%, According to Wall Street - Yahoo Finance
(NTLA) Long Term Investment Analysis - Stock Traders Daily
Capital Advisors Inc. OK Has $4.19 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
NTLAIntellia Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 - GlobeNewswire
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):